THC — Tenet Healthcare Corporation

Summary of Tenet Healthcare Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Operating Revenues: $5.6 billion
• Consolidated Adjusted EBITDA: $1.304 billion, representing a 16.3% increase year-over-year and an adjusted EBITDA margin of 23.2%.
• Adjusted Diluted EPS: Increased by 52% to $6.12 compared to Q2 2025.
• USPI Adjusted EBITDA: $542 million, up 9% year-over-year, contributing 25% to full-year 2026 adjusted EBITDA guidance.
• Hospital Segment Adjusted EBITDA: $762 million, a 22% increase year-over-year, with an 18% adjusted EBITDA margin.
• Free Cash Flow: Generated $444 million in Q2, with year-to-date adjusted free cash flow expected between $1.825 billion and $2.055 billion.
• Share Repurchases: $1.36 billion spent to repurchase 7 million shares in H1 2026, with a $2 billion increase in the share repurchase program authorized.

2. Strategic Updates and Business Highlights

• Continued focus on high acuity services led to a 10% increase in total joint replacements in ASCs.
• Strong performance in commercial managed care revenues and disciplined expense management contributed to margin strength.
• The company is actively pursuing M&A opportunities in the USPI segment, with expectations to exceed $300 million in full-year M&A spend.
• Positive results from technology-driven initiatives and expense management plans implemented at the beginning of the year.

3. Forward Guidance and Outlook

• Adjusted EBITDA Guidance: Raised to a range of $4.83 billion to $5.03 billion for FY 2026, an increase of $295 million at the midpoint.
• Net Operating Revenues Guidance: Expected to be between $21.9 billion and $22.5 billion, reflecting a $300 million increase at the midpoint.
• Anticipated third quarter adjusted EBITDA to be 23% to 24% of full-year guidance.
• Continued focus on cash flow generation and capital deployment, with a commitment to maintaining a deleveraged balance sheet.

4. Bad News, Challenges, or Points of Concern

• Exchange Revenue Decline: Down 17% year-over-year, significantly impacting overall revenue, particularly in states like Florida and Texas.
• Exchange Enrollment Uncertainty: Shift of patients from exchange coverage to uninsured status, creating potential revenue headwinds.
• Volume Pressures: Some weakness in ASC volumes attributed to a migration of lower acuity procedures to office settings, though high acuity procedures continue to grow.
• Market Dynamics: Ongoing payer mix shifts and insurance enrollment uncertainties pose risks to future revenue growth.

5. Notable Q&A Insights

• Management emphasized the importance of cost structure improvements through traditional efficiencies and clinical operations enhancements.
• Discussion on service line expansion in ambulatory settings, particularly in orthopedics and robotics, with a focus on higher acuity procedures.
• Management expressed optimism regarding volume trends, citing demographic factors and investment returns as key drivers of future growth.
• Concerns were raised about the sustainability of exchange revenues and potential impacts on future guidance, with management remaining cautious but prepared for ongoing challenges.

This summary encapsulates the key points from Tenet Healthcare's Q2 2026 earnings call, highlighting financial performance, strategic initiatives, and challenges faced by the company.